Hypertension
M-A | Blood pressure, hypertension and the risk of atrial fibrillation
1 Feb, 2023 | 13:22h | UTC
Guidelines for the management of hypertension in patients with diabetes mellitus
1 Feb, 2023 | 13:17h | UTC
Perspective | Is it time to retire the diagnosis “hypertensive emergency”?
27 Jan, 2023 | 12:26h | UTC
SR | Does reducing your salt intake help to prevent and treat chronic kidney disease in people with diabetes?
25 Jan, 2023 | 11:30h | UTC
RCT | Home vs. kiosk vs. clinic blood pressure measurement compared to 24-h ambulatory monitoring
25 Jan, 2023 | 11:28h | UTCRelated:
RCT | Effect of a multicomponent intervention delivered on a web-based platform on hypertension control
24 Jan, 2023 | 14:12h | UTC
Commentary on Twitter
Cluster RCT: A multicomponent intervention aided by web-based platform improved blood pressure control vs. usual care in China. https://t.co/bsfK5TF1hs
— JAMA Network Open (@JAMANetworkOpen) December 7, 2022
AHA Statement | Cancer therapy-related hypertension
23 Jan, 2023 | 13:46h | UTCTop Things to Know: Cancer Therapy-Related HTN – American Heart Association
Cohort Study | Increased coffee consumption linked to increased CVD risk in patients with severe hypertension
20 Jan, 2023 | 14:53h | UTCCommentaries:
Hypertension and Heavy Coffee Consumption a Bad Combo, Study Finds – TCTMD
Metomidate PET-CT vs. adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial
19 Jan, 2023 | 14:19h | UTCNews Release: Ten-minute scan enables detection and cure of the commonest cause of high blood pressure – Queen Mary University of London
RCT | Chlorthalidone (12.5-25 mg) and Hydrochlorothiazide (25-50 mg) are similarly effective for the prevention of CVD in hypertensive patients.
16 Dec, 2022 | 13:49h | UTCChlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)
Related (news release and commentaries before publication): RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
Commentary on Twitter
Patients 65 years or older with hypertension who switched from chlorthalidone to hydrochlorothiazide did not have fewer major cardiovascular events or non–cancer-related deaths than those who continued receiving hydrochlorothiazide. https://t.co/9xAiSZzxio pic.twitter.com/bIVOOiVDve
— NEJM (@NEJM) December 14, 2022
Cluster RCT | Effect of a multicomponent intervention delivered on a web-based platform on hypertension control.
8 Dec, 2022 | 13:02h | UTC
Commentary on Twitter
Cluster RCT: A multicomponent intervention aided by web-based platform improved blood pressure control vs. usual care in China. https://t.co/bsfK5TF1hs
— JAMA Network Open (@JAMANetworkOpen) December 7, 2022
Cohort Study | Adding salt to foods linked to increased risk of cardiovascular disease.
6 Dec, 2022 | 14:04h | UTCAdding Salt to Foods and Risk of Cardiovascular Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Release: Shaking less salt on your food at the table could reduce heart disease risk – American College of Cardiology
Commentaries:
Adding Salt to Food and Risk of Cardiovascular Disease – American College of Cardiology
Lower Frequency of Adding Salt to Food Linked to Lower CVD Risk – HealthDay
Review | Blood pressure elevations in hospital.
6 Dec, 2022 | 13:31h | UTCBlood pressure elevations in hospital – Australian Prescriber
Commentary: Overuse of in-hospital blood pressure medications – Flinders University
Related: Hypertension in the hospitalized patient: An update – Nefrología
M-A | Thiazide diuretics and fracture risk.
29 Nov, 2022 | 14:23h | UTC
SR | Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
22 Nov, 2022 | 13:39h | UTCSummary: Blood pressure targets in people with cardiovascular disease – Cochrane Library
Commentary on Twitter
Blood pressure targets in people with cardiovascular disease
Updated @CochraneHTN review looks at the evidence from 7 studies with 9595 people.
🤓 #plainlanguage summary & #systematicreview available on the @CochraneLibrary https://t.co/dKYyoY773f— Cochrane UK (@CochraneUK) November 19, 2022
RCT | Dual endothelin antagonist Aprocitentan is effective for resistant hypertension.
11 Nov, 2022 | 13:59h | UTCDual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION – TCTMD
Phase 2RCT | Baxdrostat reduces BP in patients with treatment-resistant hypertension.
11 Nov, 2022 | 13:57h | UTCPhase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study – TCTMD
New Drug Helps Tame Uncontrolled High Blood Pressure – HealthDay
RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
7 Nov, 2022 | 12:50h | UTCNews Release (not published yet): No difference in heart outcomes found in use of two diuretics to treat blood pressure – American Heart Association
Commentaries:
In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE – TCTMD
Diuretic Comparison Project – DCP – American College of Cardiology
RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.
4 Nov, 2022 | 13:55h | UTCRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk https://t.co/81EIwG5FQ0 pic.twitter.com/nHNmzlPbHV
— NEJM (@NEJM) November 3, 2022
M-A | Blood pressure lowering and prevention of dementia.
4 Nov, 2022 | 13:46h | UTCNews Release: Best evidence yet that lowering blood pressure can prevent dementia – George Institute for Global Health
Commentary: Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment – HealthDay
Cross-Sectional Study | Prevalence of and factors associated with high blood pressure among adolescents in India.
3 Nov, 2022 | 13:57h | UTCInvited Commentary: Prevalence of High Blood Pressure Among Youth in India and Association With Future Cardiovascular Disease – JAMA Network Open
Commentary on Twitter
1 in 3 adolescents in India have high BP, which is is associated with the trifecta of overweight/obesity, high blood sugar, high blood lipids, and can be prevented. #OAResearch https://t.co/i2Cth5ol2T
— JAMA Network Open (@JAMANetworkOpen) October 31, 2022
Cohort Study | ARBs linked to decreased incidence of epilepsy compared with other antihypertensives.
19 Oct, 2022 | 14:18h | UTCAssociation Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension – JAMA Neurology (free for a limited period)
Related:
Loneliness and health – Nature Reviews Disease Primers (if the link is paywalled, try this one)
The prevalence of loneliness across 113 countries: systematic review and meta-analysis – The BMJ
Social Isolation and Loneliness – World Health Organization
Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020 – JAMA
Perspective | The polypill: from concept and evidence to implementation.
18 Oct, 2022 | 12:55h | UTCThe polypill: from concept and evidence to implementation – The Lancet (free registration required)
Related:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Post-trial follow-up | Longer-term all-cause and cardiovascular mortality with intensive blood pressure control.
17 Oct, 2022 | 12:41h | UTCLonger-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial – JAMA Cardiology (free for a limited period)
Author Interview: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control – JAMA
Commentaries:
Benefits of Intensive Blood Pressure Control May Not Persist After Trial Intervention – HCP Live
Related:
Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial
Studies: Intensive versus Standard Blood-Pressure Control
Commentary on Twitter
In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpatient systolic BP increased by an average of 7 mm Hg for participants in the intensive treatment group. https://t.co/INSo2zYzhp #Research
— JAMA Cardiology (@JAMACardio) October 12, 2022
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.
17 Oct, 2022 | 12:37h | UTCSee also:
Homepage: The Burden of Proof Studies – Nature Medicine
The Burden of Proof studies: assessing the evidence of risk
Health effects associated with vegetable consumption: a Burden of Proof study
Health effects associated with consumption of unprocessed red meat: a Burden of Proof study
Health effects associated with smoking: a Burden of Proof study
Commentary on Twitter
A systematic review using the Burden of Proof meta-analytic method found a significant harmful effect between high systolic #bloodpressure and #ischemicheartdisease. @IHME_UW https://t.co/hewQ9nsCTh
— Nature Medicine (@NatureMedicine) October 10, 2022